These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16019524)

  • 41. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
    Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
    Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
    Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
    Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apoptotic signaling in multiple myeloma: therapeutic implications.
    Chauhan D; Hideshima T; Anderson KC
    Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of Capon in multiple myeloma.
    Shen Y; Liu H; Gu S; Wei Z; Liu H
    Tumour Biol; 2017 Jul; 39(7):1010428317713674. PubMed ID: 28671047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
    Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
    Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma.
    Barton BE; Murphy TF
    Cytokine; 2000 Oct; 12(10):1537-45. PubMed ID: 11023670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?
    Katz BZ; Tavor S
    Leuk Lymphoma; 2009 Jul; 50(7):1067-8. PubMed ID: 19557626
    [No Abstract]   [Full Text] [Related]  

  • 51. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
    Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
    Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyaluronan Controls the Deposition of Fibronectin and Collagen and Modulates TGF-β1 Induction of Lung Myofibroblasts.
    Evanko SP; Potter-Perigo S; Petty LJ; Workman GA; Wight TN
    Matrix Biol; 2015 Mar; 42():74-92. PubMed ID: 25549589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
    Ramachandran IR; Condamine T; Lin C; Herlihy SE; Garfall A; Vogl DT; Gabrilovich DI; Nefedova Y
    Cancer Lett; 2016 Feb; 371(1):117-24. PubMed ID: 26639197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
    Sharma NS; Choudhary B
    Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic antimyeloma effects of zoledronate and simvastatin.
    Schmidmaier R; Simsek M; Baumann P; Emmerich B; Meinhardt G
    Anticancer Drugs; 2006 Jul; 17(6):621-9. PubMed ID: 16917207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic Features of Multiple Myeloma.
    El Arfani C; De Veirman K; Maes K; De Bruyne E; Menu E
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The role of beta1 integrins in renal failure accompanied by multiple myeloma].
    Jawniak D; Dmoszyńska A; Goracy A
    Pol Arch Med Wewn; 1998 Oct; 100(4):300-5. PubMed ID: 10335038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
    Corso A; Ferretti E; Lazzarino M
    Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR.
    Shain KH; Dalton WS
    Mol Cancer Ther; 2001 Nov; 1(1):69-78. PubMed ID: 12467240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.